Setting | Author | Study groups (n) | In-Hospital Mortality | Reported P-value | Ref |
---|---|---|---|---|---|
Tertiary care center | Akhabue et al. (2011) | Cefepime resistant P. aeruginosa (213) | 20% | 0.007 | [61] |
Susceptible P. aeruginosa (2316) | 13% | ||||
Brooklyn Antibiotic Resistance Task Force (2002) | Carbapenem resistant P. aeruginosa (10) | 20% | > 0.05 (NS) | [60] | |
Susceptible P. aeruginosa (10) | 10% | ||||
Cao et al. (2004) | MDR P. aeruginosad (44) | 55% | 0.05 | [57] | |
Susceptible P. aeruginosa (68) | 16% | ||||
Eagye et al. (2009) | Meropenem resistant P. aeruginosa (58) | 31% | 0.152a | [53] | |
Meropenem susceptible P. aeruginosa (125) | 15% | ||||
Meropenem resistant P. aeruginosa (58) | 31% | 0.01a | |||
Control (57) | 9% | ||||
Evans et al. (2007) | Resistant P. aeruginosae (47) | 15% | 0.43 | [71] | |
Susceptible P. aeruginosa (73) | 21% | ||||
Furtado et al. (2011) | SPM-1-producing imipenem resistant P. aeruginosa (5) | 60% | 0.59 | [68] | |
Non-SPM-1-producing susceptible P. aeruginosa (24) | 75% | ||||
Gasink et al. (2006) | Fluoroquinolone resistant P. aeruginosa (320) | 24% | 0.004 | [64] | |
Fluoroquinolone susceptible P. aeruginosa (527) | 16% | ||||
Hirakata et al. (2003) | blaIMP-positive P. aeruginosa (69) | 30.4% | 0.41 | [69] | |
blaIMP-negative P. aeruginosa (247) | 25.5% | ||||
Lautenbach et al. (2010) | Imipenem resistant P. aeruginosa (253) | 17% | 0.01 | [63] | |
Imipenem susceptible P. aeruginosa (2289) | 13% | ||||
Morales et al. (2012) | MDR P. aeruginosaf (134) | 25% | < 0.05 | [49] | |
Susceptible P. aeruginosa (149) | 13% | ||||
Resistant P. aeruginosa (119) | 22% | <0.05 | |||
Susceptible P. aeruginosa (149) | 13% | ||||
Peña et al. (2013) | Non-MDR P. aeruginosa (27) | 55% | 0.33 | [56] | |
MDR P. aeruginosag (56) | 50% | ||||
Scheetz et al. (2006) | Fluoroquinolone resistant P. aeruginosa (79) | 32% | 0.731 | [65] | |
Fluoroquinolone susceptible P. aeruginosa (136) | 29% | ||||
Tam et al. (2010) | MDR P. aeruginosah (25) | 56% | 0.001 | [13] | |
Susceptible P. aeruginosa (84) | 17% | ||||
Zavascki et al. (2006) | MBL-carrying P. aeruginosa (86) | 51.2% | 0.003 | [70] | |
Non-MBL-carrying P. aeruginosa (212) | 32.1% | ||||
ICU | Lambert et al. (2011) | Ceftazidime resistant P. aeruginosa (362)b | 43% | NR | [31] |
Susceptible P. aeruginosa (1251)b | 37% | ||||
Ceftazidime resistant P. aeruginosa (82)c | 41% | ||||
Susceptible P. aeruginosa (280)c | 39% | ||||
Furtado et al. (2009) | Imipenem resistant P. aeruginosa (63) | 49% | 0.02 | [62] | |
Control (182) | 34% | ||||
Kaminski et al. (2011) | Ureido/carboxypenicillin resistant P. aeruginosa (70) | 43% | 0.56 | [66] | |
Ureido/carboxypenicillin susceptible P. aeruginosa (153) | 44% | ||||
Paramythiotou et al. (2004) | MDR P. aeruginosai (34) | 47% | 0.8 | [54] | |
Control (34) | 50% | ||||
Trouillet et al. (2002) | Piperacillin resistant P. aeruginosa (34) | 59% | > 0.05 (NS) | [67] | |
Piperacillin susceptible P. aeruginosa (101) | 50% | ||||
Tumbarello et al. 2013 | MDR P. aeruginosaj (42) | 60% | 0.01 | [55] | |
Susceptible P. aeruginosa (68) | 35% |